



**ANALYSIS OF CLINICAL CHANGES IN PATIENTS WITH ACUTE
GONORRHEA IN THE THIRD AND SIXTH DAYS AFTER
ANTIBACTERIAL THERAPY**

Ikhtiyor Ikromovich Latipov

Bukhara State Medical Institute, Bukhara city, Uzbekistan

Maxmudov Farxad Axmedovich

Bukhara State Medical Institute, Bukhara city, Uzbekistan

Ozodov Jasur Hamza o'g'li

Bukhara State Medical Institute, Bukhara city, Uzbekistan

Abstract

It has been studied what antibacterial drugs patients take to achieve good results. Based on the obtained results, the indicators were statistically processed. Which antibiotics are significantly more susceptible to gonorrhoea have been studied and determined. In the acute, subacute, chronic type of gonorrhoea on clinical course, the use of the antibiotic Cefakim + Azithromycin has shown reliable results in clinical course and laboratory analysis. The research was conducted in 76 patients with gonorrhoea aged 14 to 60 years. The diagnosis of gonorrhoea was confirmed by clinical, epidemiological and laboratory methods.

Relevance of the Topic

When determining and controlling the outcome of treatment, only a bacterioscopic method is not enough [1].

Symptomatic gonococcal urethritis in men with the help of bacterioscopy is not difficult to detect [2].

In gonorrhoea, a high-quality laboratory diagnosis is of great importance, when determining the diagnosis, it is important to find a causative agent of the disease in the pathological cleavage from the injured furnace. Currently, in our country, two methods - bacterioscopic and bacteriological (sowing) are widely used. The most common method is bacterioscopic (application of the Gram method of painting grease with methylene blue). [3].

When gonococcal infection occurs in men, an acute inflammatory process occurs in the urethra. In the urethra there is a purulent discharge of yellow-green color, accompanied by itching, redness, pain. When the disease is severe, a mixed divorce of





blood is added. Symptomatic course of the disease in men is rare in three cases raydi [4].

The incidence of gonococcal infection in Russia, according to 2014 year, was 23.9 per 100,000 population [5].

But in the end times, the incidence of urogenital gonorrhea infection with or without symptoms increases (up to 50% of men), which leads to a specific decrease in sensitivity to antibiotics. [6,7].

Only in 2012, 106.1 million cases of infection were recorded in all countries of the world [8].

According to the results of an experimental study of the sensitivity of gonococci in Moscow and Smolensk in 2000 year, data on a high degree of resistance of gonococci to penicillin and tetracycline were obtained. Emphasis is placed on the resistance of gonococci to spectinomycin (23%) and ciprofloxacin (7%), and in the second case, strains that are resistant and moderately resistant. [9].

According to the World Health Organization, more than 70 million people in the world are diagnosed with gonorrhea every year [10].

Purpose of the Scientific Work

1. To investigate whether clinical and laboratory results were achieved in 2019-2020 years when patients with gonorrhea were treated with antibacterial agents.
2. Statistical processing of the results obtained.

Material and Style

1. Dermatovenerological dispensary 2010-a study of which antibiotics were taken and their result in 200 patients who applied with acute gonorrhea in 2018.
2. In 2019-2020 years, confirmation of diagnosis through grease from 76 patients who applied with acute gonorrhea disease and to study which antibiotics were used to achieve the result.
3. Prepared grease in gram method and check it using bacterioscopic method. Comparison of results before and after treatment.





Table 1: Aobtained Results

Used antibacterial drugs	Number of patients						Acute gonorrhoea			Acute underground gonorrhoea			Chronic gonorrhoea												
	On the 3rd day of the disease		On the 6th day of the disease		On the 3rd day of the disease		On the 6th day of the disease		On the 3rd day of the disease		On the 6th day of the disease		On the 3rd day of the disease		On the 6th day of the disease										
	Purulent detachment	Redness, swelling	Itching, aching	Purulent detachment	Redness, swelling	Itching, aching	Purulent detachment	Redness, swelling	Itching, aching	Purulent detachment	Redness, swelling	Itching, aching	Purulent detachment	Redness, swelling	Itching, aching										
Linasilin	15						5(33.3%)	2(13.3%)	4(26.6%)	2(13.3%)	7(16.6%)	3(20%)	7(16.6%)	4(26.6%)	5(33.3%)	3(20%)	8(53.3%)	4(26.6%)	9(60%)	7(16.6%)	4(26.6%)	10(66.6%)	6(40%)		
Tsiprofloxacine	16						3(18.7%)	1(6.2%)	2(12.5%)	1(6.2%)	6(37.5%)	4(25%)	2(12.5%)	6(37.5%)	3(18.7%)	4(25%)	2(12.5%)	6(37.5%)	7(43.7%)	3(18.7%)	3(18.7%)	5(31.2%)	3(18.7%)	8(50%)	5(31.2%)
Biseptol	14						4(28.5%)	2(14.3%)	2(14.3%)	1(7.1%)	5(35.7%)	3(21.4%)	1(7.1%)	5(35.7%)	2(14.3%)	5(35.7%)	2(14.3%)	5(35.7%)	3(21.4%)	4(28.5%)	2(14.3%)	7(50%)	4(28.5%)		
Azithromycin	15						2(13.3%)	1(6.6%)	1(6.6%)	0	3(20%)	1(6.6%)	0	3(20%)	2(13.3%)	0	3(20%)	1(6.6%)	4(26.6%)	1(6.6%)	3(20%)	0	4(26.6%)	1(6.6%)	
Cefakim+	16						1(6.2%)	0	1(6.2%)	0	2(12.5%)	0	0	2(12.5%)	1(6.2%)	0	2(12.5%)	0	3(18.7%)	1(6.2%)	2(12.5%)	0	3(18.7%)	1(6.2%)	



According to him, 15 patients with tetracycline antibiotic therapy received 86% of the clinical symptoms before the start of treatment, clinical symptoms on the 3rd day after the start of treatment are S5(33.3%), redness and swelling 4(26.6%), itching and itching 7(16.6%), clinical signs on the 6th day after the start of treatment are 2(13.3%), redness and swelling 2(13.3%), clinical signs in 3-day after the start of treatment acute underground gonorrhoea purulent discharge 7(16.6%), redness and swelling 5(33.3%), itching and aching 8(53.3%), clinical signs in 6-day after the start of treatment acute underground gonorrhoea purulent discharge 4(26.6%), redness and swelling 3(20%), itching and aching 4(26.6%), clinical signs in 3-day after the start of treatment chronic gonorrhoea purulent discharge 9(60%), redness and swelling 7(16.6%), itching and aching 10(66.6%), clinical signs in 6-day after the start of treatment purulent discharge in gonorrhoea was 4(26.6%), redness and swelling 4(26.6%), itching and aching 6(40%).

Ciprofloxacin antibiotic was administered in 16 patients and the following results were obtained. Clinical signs before the start of treatment 82%, clinical signs on the 3rd day after the start of treatment 3% purulent discharge in acute gonorrhoea 3(18.7%), redness and swelling 2(12.5%), itching and irritation 6(37.5%), clinical signs on the 6th day after the start of treatment 1(6.2%) purulent discharge in acute gonorrhoea, redness and swelling 1(6.2%), itching and-clinical signs of acute subcutaneous gonorrhoea purulent discharge 6(37.5%), redness and swelling 4(25%), itching and itching 6(37.5%), clinical signs in 6-day after the start of treatment acute underground gonorrhoea purulent discharge 3(18.7%), redness and swelling 2(12.5%), itching and aching 3(18.7%), clinical signs in 3-day after the start of treatment chronic gonorrhoea purulent discharge 7(43.7%), redness and swelling 5(31.2%), itching and aching 8(50%), clinical signs in 6-day after the start of treatment chronic gonorrhoea in gonorrhoea, purulent discharge 3(18.7%), redness and swelling 3(18.7%), itching and bitterness 5(31.2%).

Clinical signs before the start of treatment with Bisseptol antibiotics in 14 patients 87%, clinical signs in 3 days after the start of treatment with acute gonorrhoea purulent discharge 4(28.5%), redness and swelling 2(14.3%), itching and irritation 5(35.7%), clinical signs in 6 days after the start of treatment with acute gonorrhoea purulent discharge 2(14.3%), redness and swelling 1(7.1%), itching 21.4%), clinical signs on the 3rd day after the start of treatment acute subcutaneous purulent Detachment 5(35.7%), redness and swelling 3(21.4%), itching and aching 5(35.7%), clinical signs in 6-day after the start of treatment acute underground gonorrhoea purulent discharge



3(21.4%), redness and swelling 1(7.1%), itching and aching 2(14.3%), clinical signs in 3-day after the start of treatment chronic gonorrhea purulent discharge 5(35.7%) redness and swelling 4(28.5%), itching and aching 7(50%), clinical signs in 6-day after the start of treatment in gonorrhea, purulent discharge 3(21.4%), redness and swelling 2(14.3%), itching and bitterness 4(28.5%).

Azithromycin antibiotic was administered in 15 patients and the following results were obtained. Clinical signs on the 3rd day after the start of treatment acute gonorrhea purulent discharge 2(13.3%), redness and swelling 1(6.6%), itching and aching 3(20%), clinical signs on the 6th day after the start of treatment acute gonorrhea purulent discharge 1(6.6%), redness and swelling 0, itching and aching 1(6.6%), clinical signs on the 3rd day after the start of purulent Detachment 3(20%), redness and swelling 2(13.3%), itching and bitterness 3(20%), clinical signs on the 6th day after the start of treatment acute subcutaneous purulent Detachment 1(6.6%), redness and swelling 0, itching and aching 1(6.6%), clinical symptoms on Day 3 after the start of treatment chronic gonorrhea purulent discharge 4(26.6%), redness and swelling 3(20%), itching and aching 4(26.6%), clinical symptoms on Day 6 after the start of treatment chronic gonorrhea purulent discharge 1(6.6%), redness and swelling 0, itching and aching 1(6.6%).

Cefacime+azithromycin antibiotics were used in 15 patients and the following results were obtained. Clinical signs on the 3rd day after the start of treatment acute gonorrhea purulent discharge 1(6.2%), redness and swelling 1(6.2%), itching and aching 2(12.5%), clinical signs on the 6th day after the start of treatment acute gonorrhea purulent discharge, redness and swelling, itching and aching 0. Clinical signs in 3-day after the start of treatment acute underground gonorrhea purulent discharge 2(12.5%), redness and swelling 1(6.2%), itching and irritation 2(12.5%), clinical signs in 6-day after the start of treatment acute underground gonorrhea purulent discharge 1(6.2%), redness and swelling 0, itching and irritation 0. Clinical signs in the 3rd day after the start of treatment chronic gonorrhea purulent discharge 3(18.7%), redness and swelling 2(12.5%), itching and soreness 3(18.7%), clinical signs in the 6th day after the start of treatment chronic gonorrhea purulent discharge 1(6.2%), redness and swelling 0, itching and soreness 1(6.2%).

Conclusion

it should be said that acute, acute subcutaneous and chronic gonorrhea disease, which group of antibiotics is currently used, has been analyzed for the possibility of achieving better results. Laboratory and clinical changes were studied. Accordingly, it was found that the results obtained when applied with the addition of antibacterial



drugs Cefakim and azithromycin, which gave a good result among them, were reliable. The results of this analysis were shown on the basis of the above tables. Reliably ($R < 0.05 < 0.001$) changes of the above indicators were determined.

Literature

1. Махмудов, Ф. А., & Латипов, И. И. (2019). Атопический дерматит: иммунопатогенез и стратегия иммунотерапии. *Новый день в медицине*, (4), 195-200.
2. Latipov, I. I., Axmedovich, M. F., & Hamzao'g'li, O. J. (2021). Evaluation of the quality of life of vitiligo patients by the effectiveness of combination therapy using the dermatology life quality index (dlqi). *Web of Scientist: International Scientific Research Journal*, 2(10), 55-63.
3. Maxmudov, F. A., & Latipov, I. I. (2019). The immunopathogenesis of atopic dermatitis and strategy of immunotherapy. *Новый день в медицине*, (4), 53-57.
4. Latipov, I. I., Axmedovich, M. F., & Hamzao'g'li, O. J. (2021). Patients with a Diagnosis of Gonorrhoea are Registered in Bukhara Region and Depending on the Clinical Course of the Disease, Separation into Age and Gender. *International Journal of Innovative Analyses and Emerging Technology*, 1(6), 135-138.
5. Latipov, I. I., Axmedovich, M. F., & Hamzao'g'li, O. J. (2021). Clinical and immunological aspects of pathogenesis and complex therapy of vitiligo. *Academia Globe: Inter-science Research*, 2(11), 14-20.
6. Sh, V. A., Saipova, N. S., & Azizov, B. S. (2021). Clinical case of papulonecrotic tuberculosis of the skin. *Innovative Technologica: Methodical Research Journal*, 2(11), 48-55.
7. Axmedovich, M. F., Ikromovich, L. I., & Hamzao'g'li, O. J. (2021). Statistics of the incidence of cutaneous leishmaniasis in the Bukhara region, depending on age, gender and region. *Middle European Scientific Bulletin*, 17, 373-377.
8. Азизов, Б. С., Салимова, И. У., & Аюпова, Ш. Т. (2020). Вульгарная пузырчатка и ее аспекты. *Вестник магистратуры*, (12-2), 4.
9. Азизов, Б. С., Агзамходжаева, С. С., & Салимова, И. У. (2020). Современный взгляд на проблему угревой болезни. *Medicus*, (2), 21-24.
10. Maxmudov, F. A., Rahmatov, O. B., Latipov, I. I., Rustamov, M. K., & Sharapova, G. S. (2021). Intravenous laser blood irradiation in the complex treatment of patients with cutaneous leishmaniasis. *48(9)*.
11. Karimkulovich, R. M., & Axmedovich, M. F. (2021). The use of Retinoids in the Approach to the Cosmetic Treatment of Acne. *Central Asian Journal Of Medical And Natural Sciences*, 2(6), 44-48.





12. Karimkulovich, R. M. (2021). Analysis of the Efficiency of the Application of Balm "Dilasen" in Patients with Ache Vulgar. *Central asian journal of medical and natural sciences*, 2(5), 394-398.
13. Djumayevich N. F. Macro-Microscopic Anatomy and Reactive Changes in the Testimonial Appendices under Exposure to Magnesium Chlorate in Postnatal Ontogenesis // *International Journal of Innovative Analyses and Emerging Technology*. – 2021. – T. 1. – №. 6. – C. 152-155.
14. Abdurasulovich S. B. et al. Age and metastatic characteristics of mammary cancer // *ResearchJet Journal of Analysis and Inventions*. – 2021. – T. 2. – №. 09. – C. 18-21.
15. Abdurasulovich, Sanoev Bakhtiyor. "Morphological and morphometric characteristics of the placenta in normal pregnancy." *editor coordinator* (2021): 492.

